3 c ^ 
c/) O n 
'w' 'U 
P/FDA 
P/FDA 
and NIH 
P/FDA 
and NIH 
<5 
6. g 
# 
Deaths 
cu 
0k 
0k 
0k 
Adverse 
Effects 
cu 
eu 
0k 
Ok 
a" S k 
| S £ 
Jp 1 
£ % H 
a. 
&i 
Ok 
0k 
pi ifis 
III! I 
0 I®.: 
cu 
Ok 
0k 
0k 
Patient 
Accrual 
To 
Date; 
o 
o 
O 
O 
151 
1 1 1 
P< 
'O 
<N 
vO 
30 
(3 groups 
of 10) 
Vector 
Supplier 
no 
U. of IL, 
Chicago 
ND 
LLD 
Packag- 
ing Cell 
PA317 
|ls 
a. 5 
O ^ 
PA317 
PA317 
Vector/ 
Gene 
GITkSvNa 
(HS-tk cDna) 
pZipNeoSv- 
IL2 
pMJT 
(hairpin 
ribozyme) 
; Z 
^k 
O : 
u ~ 
«B.Ss ; 
0k 
Ok 
0k 
Ok ' 
Patients 
Cancer/ 
Brain 
Cancer/ 
Melanoma 
HIV( + ) 
Cancer/ 
Melanoma 
M/T 
H 
H 
H ; 
H 
NTH 
Approval 
Date 
10-7-93 
0k 
0k 
0k 
RAC 
Approval 
Date 
9-9-93 
9-10-93 
9-10-93 
1 
dv 
Institution 
St. Jude 
U. of IL, 
Chicago 
U. of San 
Diego, CA 
UCLA 
s 
Kun, et al. 
Das Gupta, 
et al. 
Wong-Staal, 
et. al. 
Economou, 
et. at. 
V" V 
I 
9309-055 
9SO-60C6 
9309-057 
i 
i 
U — 
| 9309-058 
1 
i 
* 
»"k 
| 
*8 
a 
Recombinant DNA Research, Volume 18 
[587] 
